Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Announces Reversal of Summary Judgment in Ultracet(R) ANDA Patent Litigation
Date:8/27/2009

DETROIT, Aug. 27 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) announced today that a US Federal Circuit Court has reversed a portion of a previously decided summary judgment on ANDA Patent litigation between Ortho McNeil and Caraco regarding Ultracet(R). The court has remanded the litigation to a lower court for further proceedings. The court did find that a portion of the patent was not valid. Caraco believes in the merits of its case and is evaluating its further options.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic and private-label pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limitation, the words "believe" or "expect" and similar expressions are intended to identify forward-looking statements. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission, including Part I, Item 1A of our most recent Form 10-K, and include but are not limited to: information of a preliminary nature that may be subject to adjustment, potentially not obtaining or delay in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, development by competitors of new or superior products or less expensive products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launches, dependence on few products generating majority of sales, product liability claims for which the Company may be inadequately insured, and other risks identified in this report and from time to time in our periodic reports and registration statements. These forward-looking statements represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements.


'/>"/>
SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Imitrex(R) Tablets
2. Caraco Pharmaceutical Laboratories, Ltd. Announces Settlement of Ethyol(R) ANDA Patent Litigation
3. Caraco Pharmaceutical Laboratories, Ltd. Announces Change to Executive Team as Jitendra N. Doshi Assumes Position of CEO
4. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2010
5. Caraco Pharmaceutical Laboratories, Ltd. Announces Filing of Purported Class Action Lawsuits
6. Forest Laboratories and H. Lundbeck A/S Enter Into Settlement Agreement With Sun and Caraco Related to LEXAPRO(R) Patent Litigation
7. Caraco Pharmaceutical Laboratories, Ltd. Enters Into Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro(R) (escitalopram oxalate) ANDA Patent Litigation
8. Caraco Pharmaceutical Laboratories, Ltd. Announces an Indefinite Reduction in its Workforce
9. Caraco Pharmaceutical Laboratories, Ltd. Updates on Financial Position
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Action
11. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Fiscal Year 2009, Updates on FDA Inspection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2016)... Michigan (PRWEB) , ... February 07, 2016 , ... ... organ prolapse with the latest techniques and the most minimally invasive approaches. , ... organ prolapse, particularly after menopause. Other risk factors include surgery to the pelvic ...
(Date:2/7/2016)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... February 07, ... ... women on Friday in recognition of National Wear Red Day. National Wear Red ... heart disease and stroke in women. Heart disease and stroke cause 1 in 3 ...
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart Holdings, Inc. ... organizations with the tools and information to lower the costs, and increase the ... cost of providing employee healthcare benefits by as much as 22%:, + ...
(Date:2/7/2016)... ... February 07, 2016 , ... ... Plastics, has added Kybella® to his medical and surgical expertise. Technically known as ... FDA injectable medication used as a non-surgical alternative for reduction of fat below ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT:     , This conference ... estimated 5000 perioperative nurses in attendance to study the latest evidence-based recommendations ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... CHAPEL HILL, N.C. , Feb. 5, 2016 /PRNewswire/ ... sector has been slower than other industries to embrace ... that come with utilization. On the medical side, organizations ... to improve everything from clinical trials to adherence. ... recent research from benchmarking firm Best Practices, LLC, Big ...
(Date:2/5/2016)... , Feb. 5, 2016 Amgen (NASDAQ: ... Annual Global Healthcare Conference at 9:15 a.m. ET on ... . David W. Meline , executive vice president ... conference. Live audio of the presentation can be accessed from ... Investors. A replay of the webcast will also be available ...
(Date:2/5/2016)...  Redwood Scientific Technologies, Inc. announced today the development ... women balance their hormones. This product will be featuring ... Jason Cardiff , President and CEO. "I am proud ... millions of women across the country and around the ... Our research and development team is confident that through ...
Breaking Medicine Technology: